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Abstract  
It is already more than a century since the pioneering work of the Nobel Laureate Ehrlich gave 
birth to the side chain theory1, 2 which helped to define antibodies and their ability to target 
specific biological sites. However, the use of antibodies is still restricted to the extracellular space 
due to the lack of a suitable delivery vehicle for the efficient transport of antibodies into live cells 
without inducing toxicity. In this work, we report the efficient encapsulation and delivery of 
antibodies into live cells with no significant loss of cell viability or any deleterious affect on the 
cell metabolic activity. This delivery system is based on poly(2-(methacryloyloxy)ethyl 
phosphorylcholine)-block-(2-(diisopropylamino)ethyl methacrylate), (PMPC-PDPA), a pH-
sensitive diblock copolymer3 that self-assembles to form nanometer-sized vesicles, also known as 
polymersomes,4 at physiological pH. These polymersomes can successfully deliver relatively high 
antibody payloads within live cells. Once inside the cells, we demonstrate that these antibodies 
can target their epitope by immune-labelling of cytoskeleton, Golgi, and transcription factor 
proteins in live cells. We also demonstrate that this effective antibody delivery mechanism can be 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
42
7.
1 
: P
os
te
d 
8 
M
ay
 2
01
0
 2 
used to control specific subcellular events, as well as modulate cell activity and pro-inflammatory 
process. 
 
There is an emerging need in both pharmacology and within the biomedical industry to develop new 
tools to investigate intracellular mechanisms, since a greater understanding of such processes should 
ultimately provide innovative therapeutics. The efficient delivery of functionally active proteins within 
cells is a potentially powerful research strategy, especially for intracellular antibodies5. Nevertheless, 
the available methodologies for intracellular delivery are often restricted by adverse effects on the 
protein function and stability, mainly due to the extensive chemical modifications that are normally 
required for such approaches6. Recent strategies for the intracellular delivery of functional proteins 
include the use of liposomes to encapsulate both proteins and genes for intracellular delivery7, 
antibody delivery via protein transduction domains (PTD)8, membrane receptors and transport signals9-
11
, viral vectors12, microinjection13 or electroporation14. However, each of these methods lack 
convenience and effectiveness and moreover are often compromised by cellular toxicity15. Some of 
these limitations have been overcome by delivering transcriptionally-active DNA into cultured cells to 
express a desired protein, which then acts as an intracellular target16.  
Herein we present a non-cytotoxic delivery system based on a pH-sensitive diblock copolymer that 
self-assembles at physiological pH to form nanometer-sized polymersomes. These polymersomes 
successfully deliver functional antibodies into the cytoplasm. More specifically, polymersomes were 
formed using a PMPC-PDPA diblock copolymer  comprising a highly biocompatible poly(2-
(methacryloyloxy)ethyl phosphorylcholine) (PMPC) block and a pH-sensitive poly(2-
(diisopropylamino)ethyl methacrylate) (PDPA) block (with a pKa of ~ 5.8-6.6, depending on the ionic 
strength)
17
. Polymersomes are uptaken by cells via endocytosis
18
 and hence experience a rapid drop in 
local pH. Under these conditions, the polymersomes dissociate rapidly to form individual copolymer 
chains. This causes a sudden increase (by several orders of magnitude) in the number of species that 
are present and the consequent osmotic shock ruptures the endosomal membrane. Cell internalization 
kinetics can be precisely tuned by careful control of polymersome size and surface topology
18
 and 
these polymersomes have been employed for the efficient intracellular delivery of plasmid DNA
19
 and 
various fluorophores.
20
 Moreover, the presence of PMPC-PDPA polymersomes within cells 
consistently has a negligible effect on cell viability and stress levels over a broad range of cell types, 
including both primary cells and cell lines.
18, 21, 22
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Figure 1. Effective delivery of an antibody within live cells. Confocal Laser Scanning Microscopy (CLSM) micrographs 
of live HDF cells recorded using DIC, red channel and ‘composed image’ modes after polymersome-mediated delivery of 
AlexaFluor546-IgG. (a) Fluorescence Activated Cell Sorting (FACS) of HDF cells after 2 h incubation with 
AlexaFluor546-IgG-loaded polymersomes (b). Quantification of antibody uptake as a function of incubation time (c).  
 
Results 
 
Cytosolic antibody delivery 
In order to assess effective cytosolic delivery of antibody within live cells, we encapsulated 
AlexaFluor546-labelled IgG antibodies within PMPC-PDPA polymersomes, followed by incubation 
with primary live human dermal fibroblasts (HDF) for various time periods. The treated cells were 
subsequently washed thoroughly and analysed by confocal microscopy (Figure 1a), Fluorescence 
Activated Cell Sorting (FACS) (Figure 1b) and fluorescence spectroscopy after lyses (Figure 1c). 
Confocal Laser Scanning Microscopy (CLSM) revealed that the fluorescently-labelled antibodies were 
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delivered effectively within the cytosol, almost regardless of the cell type. This was also confirmed by 
FACS analysis, as shown in Figure 1b, where HDF cells treated with AlexaFluor546-labelled IgG 
loaded polymerosme were approximately an order of magnitude more fluorescent than either untreated 
control cells or cells treated with free antibody. The extent of antibody delivery was further assessed 
by incubating cells with polymersomes for different times and quantifying the amount of intracellular 
antibody present after cell lysis by uv-visible absorption spectroscopy.  Cell internalization kinetic data 
(see Figure 1c) confirm that (i) uptake of antibody-loaded polymersomes is detectable within 30 
minutes of incubation and (ii) the fluorescence intensity rapidly increases within the first 2 h of 
incubation time (N.B. Cells treated with free antibodies exhibited no fluorescence in control 
experiments). The increase in fluorescence intensity per cell can be attributed to the intracellular 
release of the AlexaFluor 546- IgG. These data are consistent with previous work from our group, 
which indicated that polymersome internalization increases linearly with time, despite cellular 
division.
18, 21
 Volumetric analysis of antibody distribution within the cells using CLSM allows precise 
imaging of cells at different focal planes. Live cells exhibit strong fluorescent signals from the cytosol 
(Figure S1a-b). These results were compared with a traditional immunolabelling method (Figure S1c-
d) where permeabilised fixed cells were treated with the same concentration of antibody (AlexaFluor 
546 goat Anti-mouse IgG).  
The precise mechanism for the intracellular delivery of antibodies is not yet known. However, we have 
observed22, 23 that, in order to achieve efficient endocytosis, the polymersome surface chemistry (and 
hence the cell binding ability) is crucial in order to determine whether effective and fast endocytosis is 
achieved. We have demonstrated that polymersome entry is controlled by endocytosis and also 
identified some of the steps in the entry mechanism, such as acidification and microtubule-guided 
transportation.18 Although further work is needed to elucidate the uptake mechanism in more detail, we 
verified that endosome escape is definitely triggered by the pH-sensitive nature of the polymersomes. 
18, 21
 To further validate the entry mechanism, and more importantly the endosome escape, we 
encapsulated 15 nm gold-labelled IgG antibodies within the polymersomes. HDF cells were treated for 
24 h and subsequently analysed by transmission electron microscopy (TEM). The 15 nm gold was 
easily identifiable within the cells and only those cells treated with antibody-loaded polymersomes 
displayed gold-IgG within the cytosol (Figure S2). In Figure 2a a high magnification TEM micrograph 
clearly confirms this finding in more detail. All the various steps such as polymersome endocytosis, 
trafficking vesicle, endosomal escape and, more importantly, the delivered antibody within the cytosol 
(circled) can be observed. This confirms our hypothesis of endosomal membrane destabilisation and 
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subsequent delivery of the antibody within the cytosol.  In Figure 2b, a detailed mechanism for 
polymersome-mediated antibody delivery is proposed, showing the various steps.  
 
 
Figure. 2. Mechanism of cytosolic delivery of antibodies. TEM image obtained for a HDF cell after 24 h exposure to 
polymersomes loaded with 15 nm gold-labelled IgG antibodies (a). Specific events such as polymersome endocytosis (PE), 
trafficking vesicle (TV) and the early endosome (EE) escape can be observed. The gold-labelled antibodies delivered 
within the cell cytosol are circled. A schematic representation of polymersome-mediated delivery of antibodies within 
mammalian cells (b). 
 
Subcellular targeting 
We have demonstrated that this novel methodology is comparable to a traditional immunolabelling 
technique in terms of signal intensity. Figures S1a and S1c show similar signal density distributions for 
the same antibody delivered into both live cells (by means of polymersomes) and fixed cells. 
Accordingly, the next step was to demonstrate that the antibody payload retained its functionality. We 
tested subcellular targeting of cytosolic protein targets within the cell by encapsulating antibodies 
targeting specific intracellular epitopes. In Figure 3a, polymersomes loaded with mouse monoclonal 
anti-human--tubulin FITC-labelled IgG (anti -tubulin) were exposed to live HDF cells for 24 h. 
Tubulin filaments were positively stained to confirm the targeting and functionality of the antibodies. 
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This suggests that the polymersomes play a protective role during intracellular delivery as well as 
allowing the subsequent release of the antibody within the cell cytosol. Comparing both live and fixed 
specimens revealed disparities in the labelled structures. With traditional fixative techniques, 
paraformaldehyde crosslinks
24
 the cytoskeleton, resulting in long tubular structures being stained. 
However, this effect was not observed in live samples. The -tubulin labelling revealed shorter, more 
dynamic fibres. This is very much in line with the plasticity of the motile cytoskeleton of the cell
25
. 
 
Figure 3: Distribution of internalised polymersomes encapsulating intracellular epitope-targeting antibodies. CLSM 
imaging of the intracellular delivery of polymersomes loaded with mouse monoclonal anti-human--tubulin FITC-labelled 
IgG into live HDF cells. Live CLSM cell imaging of the intracellular delivery of polymersomes encapsulating AlexaFluor 
546-Rabbit polyclonal to human NFB-p65 IgG into HDF cells unstimulated (b) and stimulated with Lipopolysaccharides 
(LPS) (c). 
 
Achieving live imaging of structural proteins is very useful for descriptive biology, however, the real 
challenge for the intracellular delivery of antibodies is the development of new tools to interrogate live 
cells for the study of functional proteins (such as those involved in cell signalling, stem cell 
differentiation, immune response or cell cycle) in their specific biological context, rather than using 
cell fixation techniques (as in traditional immunolabelling). On the one hand, such in situ studies 
should reveal vital mechanistic information, but perhaps more importantly modulation of the activity 
of these proteins might provide a new avenue for pharmacological therapies. Thus we evaluated the 
ability of these polymersomes to mediate intracellular delivery of antibodies to one well-known 
example of a functional protein: the nuclear transcriptional factor, NF-B.
26
 This is an evolutionarily 
conserved protein complex that plays a pivotal role in the immune system by modulating the 
expression of inducers and effectors in response to pathogens, cellular stress, free radicals etc.27 Under 
normal conditions, NF-kB complexes are localized in the cytoplasm and are typically bound to a 
family of inhibitory proteins (IkBs) that are known inhibitors of NF-kB. Upon receptor ligation and 
recruitment of receptor proximal adaptor proteins, a cascade of events is triggered that ultimately leads 
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to IkB degradation. This exposes the NF-kB nuclear location sequence (NLS) allowing its 
translocation to the nucleus.27, 28 When cells are not stimulated, the inactive NF-B is mainly located 
within the cell cytoplasm. As shown in Figure 3b, imaging of live non-stimulated cells treated with 
polymersomes loaded with a AlexaFluor 546-Rabbit polyclonal to human NFB-p65 IgG (anti p65) 
reveals a distribution of this antibody within the cell cytosol. The nuclear translocation of NF-B is 
triggered on cellular stimulation using lipopolysaccharide (LPS), hence treatment with antibody-
loaded polymersomes localises the payload mainly within the nuclear region (Figure 3c). 
 
Intracellular expression of antibodies is a non-trivial problem29, 30. Antibodies are designed to be 
extruded through reticulum and secreted into the extracellular space within B-cells. The main 
challenge for the retention of these proteins inside the cytosol is the redox environment of the cytosolic 
compartment29, 30. In principle, a system that is able to deliver already fully-functional antibodies may 
overcome such problems. In our work, HDF cells were incubated for 24 h with polymersomes loaded 
with mouse-anti human-Golgin-97monoclonal IgG (which acts as a primary antibody). Following this 
treatment, cells were treated for 2 h with polymersomes encapsulating AlexaFluor 546 goat Anti-
mouse IgG (which acts as a secondary antibody) to perform double immunolabelling within live cells 
(see Figures 4a and 4b). As an internal control, fixed HDF cells were labelled using a traditional 
immunolabelling technique with both antibodies (Figures 4c and 4d). Both techniques allowed 
similar staining of the Golgi structure to be achieved. This suggests that polymersome-mediated 
delivery maintains the functional structure of the antibody after intracellular release of the 
payload. Furthermore, the effective staining achieved using secondary and primary antibodies 
allows maximun flexibility in selecting the target, as well as enhancing the signal. Indeed secondary 
antibodies are often designed to target more than one epitope of the primary one allowing 
multilabelling and increased the signal to noise ratio.  N
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Figure 4. Double immunolabelling and STED microscopy. Live immunolabelling of Golgin-97 in HDF cells. (a-b) HDF 
cells treated with polymersomes loaded with mouse-anti human-Golgin-97monoclonal IgG for 24 h and subsequently with 
AlexaFluor 546 goat Anti-human IgG for 2 h before being visualised by CLSM. (c-d) Conventional immunolabelling of 
Golgi apparatus. Confocal and STED imaging of live (e) and conventional (f) immunolabelling of nuclear protein Lamin 
A/C using ATTO647 dye-labelled rabbit-anti human-lamin-monoclonal IgG.  
 
Recently, optical imaging has been revolutionised by the invention of stimulated emission 
depletion microscopy (STED) microscopy.
31-33
 An ingenious combination of two concentric lasers 
allows one laser pulse to excite the specimen while the second laser pulse “depletes” the excited 
states of any fluorophores. This set-up enables a resolution of tens of nanometres to be achieved. 
STED has been used to analyse sub-cellular structures and processes in their native environment 
with minimal perturbation. However, STED imaging is limited to only a few dyes that have the 
correct photophysical characteristics to be both excited and depleted with high quantum yields.
32
 
Herein, we have evaluated our polymersome-based technology to deliver functional antibodies 
within live cells using STED-optimised ATTO-647 anti human lamin IgG. As shown in Figure 4e 
sufficient antibodies are delivered to allow STED imaging and hence produce high resolution 
images of live cells that are comparable to those achieved using the traditional fixation methods 
(Figure 4f). 
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Therapeutic impact 
In addition to their use as investigative tools, antibodies are of increasing interest as therapeutic agents; 
either in combination with drugs or as blocking agents for specific signals.34 Indeed, therapeutic 
antibodies are one of the fastest developing areas of the biopharmaceutical industry, with total annual 
sales expected to exceed $50 billion within the next few years.  There are 23 therapeutic products 
based on monoclonal-neutralising antibodies and 3 based on antibody fragments that are currently 
available, with a market impact of over $1 billion sales per year).35 However, despite numerous 
attractive intracellular targets, antibody therapeutics have been principally restricted to the 
extracellular space. This is generally due to the lack of an efficient delivery vehicle for the transport of 
functional polypeptides within cells without inducing cytotoxicity. It appears evident that the herein 
proven ability to deliver functional antibodies can have a tremendous impact on designing new 
therapies based on ad-hoc engineered antibodies. To demonstrate this potential, we delivered labelled 
and non-labelled rabbit polyclonal to human NFB-p65 IgG in order to target the p65 subunit of the 
nuclear transcription factor NF-B. As shown in Figures 3c and 3b, the polymersome-mediated 
delivery of anti-p65 antibodies effectively targeted NF-kB, either when the complex is within the 
cytosol or in the nucleus. Furthermore, we examined whether the delivery of the anti-p65 antibody had 
an effect on the ability of NF-B to translocate to the nucleus upon activation. Using CLSM (see 
Figure 5a) we observed that, on increasing the antibody load inside the cells, the majority of the 
fluorescent signal originates from the perinuclear area of activated cells. 
This suggests that the antibody hinders the translocation of the NF-B to the nucleus. This finding was 
corroborated by quantification of the NF-B translocation via immunofluorescence as a function of the 
delivered antibody concentration. While either untreated cells or cells treated with empty 
polymersomes displayed effective translocation upon LPS stimulation, this effect is inhibited as cells 
are treated with increasing concentrations of antibody, with almost full inhibition being observed at the 
highest antibody concentrations, see Figure 5b. Due to the deficient NF-B translocation, the profile of 
pro-inflamatory cytokine expression upon LPS activation was considerably reduced in HDF cells 
(Figures 5c and 5d). This proof-of-concept experiment demonstrates the potential therapeutic use of 
neutralising antibodies. Normal skin tissue contains non-hematopoietically-derived cells such as 
fibroblasts, keratinocytes and endothelial cells. These can produce NF-B inducible cytokines which 
stimulate and recruit T-cells into the skin upon inflammation.36,37 In particular, human dermal 
fibroblasts are known to release different amounts of pro-inflammatory cytokines (IL-6, IL-8) upon 
LPS induced NF-B activation.36,38,39 Here we use a simple example where neutralising antibodies that 
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hinder the translocation of NF-B have a clear effect (at the protein level) on the expression of pro-
inflammatory cytokines. Moreover, translation of this particular example (NF-B targeting) in order to 
target many different epitopes of interest for particular biologica/therapeutical purposes should be 
straightforward. 
 
 
 
Figure. 5. HDF cells after 6 h incubation with polymerosmes delivered AlexaFluor546-Anti-p65-NFB (red) and 
stimulated for 2 h with 1 μg/ml of LPS. NF-B accumulates around the perinuclear area (a). Cellular nucleic acids (DNA 
and RNA) were co-stained with a green SYTO9 dye. Quantification of the NF-B translocation (b) by immuno-labelling 
post stimulation of LPS (2 h) either untreated or treated with different concentrations of polymersomes delivering Anti-
p65-NFB. Quantification of cytokine IL-6 (c) and IL-8 (d) release in the conditioned media of HDF cells 24 h after 
exposure to different concentrations of polymersomes delivering Anti-p65-NFB. 
 
Discussion 
We have shown that, using the appropriate polymersome-based delivery vehicle, relatively large 
antibodies can be efficiently delivered with retention of their functionality within live cells without 
inducing cellular death or stress. As the pH-sensitive polymersomes are internalised and exposed to the 
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acidic environment of the endosome rapid dissociation occurs, thereby promoting a local increase in 
the number of particles with a subsequent increase in the osmotic pressure. To overcome this pressure, 
we postulate that the excess concentration may be released outside the endosome via temporary 
membrane disruption, allowing delivery of the polymersome payload to the cytosol. We provide 
experimental evidence based on FACS, CLSM and TEM to support this hypothesis. In particular, 
polymersome-induced endosome destabilisation is sufficient to mediate the release of large 15 nm 
gold-labelled antibodies (Figure 2a). We have demonstrated the integrity of the delivered antibodies by 
effective intracellular epitope targeting of labelled antibodies, as judged by CLSM imaging. The data 
shown in Figures 3 and 4 clearly demonstrate that this approach could be used for live cell imaging, 
which enables immunolabelling studies of intracellular events to be conducted without the intrinsic 
limitations associated with cell fixation. This opens up a new window on biological research by 
revealing relevant intracellular details in real time and, if combined with state-of-the-art optical 
techniques such as STED imaging, this approach can have substantial impact on both cellular biology 
and biophysics.  
Finally, polymersomes are known to be non-ergodic enclosed structures containing a tightly entangled 
membrane
40
. In contrast to the more dynamic, thin-walled liposomes, the robust nature of 
polymersome membranes prevent leakage of the payload and thus protects the encapsulated protein 
from the environment
4
. We have already confirmed that polymersomes offer an excellent platform 
technology for the efficient delivery of various species via both topical and systemic administration.
41
 
In particular, PMPC-PDPA polymersomes can deliver antibodies intracellularly in vivo with little or 
no associated toxicity or morbidity.
42
 In principle, the combination of effective delivery across cell 
membranes with state-of-the-art antibody engineering has the potential to revolutionise the treatment 
of many diseases.  
 
Materials and methods 
 
Materials. 2-(Methacryloyloxy)ethyl phosphorylcholine (MPC; > 99 %) was kindly donated by 
Biocompatibles UK Ltd. 2-(Diisopropylamino)ethyl methacrylate (DPA) was purchased from 
Scientific Polymer Products (USA). Copper(I) bromide (CuBr; 99.999 %), 2,2-bipyridine (bpy), 
methanol and isopropanol were purchased from Aldrich and were used as received. The silica used for 
removal of the ATRP copper catalyst was column chromatography grade silica gel 60 (0.063-0.200 
mm) purchased from E. Merck (Darmstadt, Germany). 2-(N-Morpholino)ethyl 2-bromo-2-
methylpropanoate (ME-Br) initiator was synthesised according to a previously reported protocol 
43
.Chloroform was purchased from Fisher Scientific, phosphate buffer saline (PBS) tablets from Oxoid 
Ltd, and sepharose 4B from Sigma-Aldrich. DMEM media and foetal calf serum were bought from 
Biosera (UK) and L-glutamine, penicillin streptomycin and Amphotericin B were bought from Sigma 
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(UK).  Collagenase A was purchased from Boehringer-Mannheim (Lewes, UK).  For the MTT-ESTA 
assay, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) was purchased from 
Sigma-Aldrich (UK) and hydrochloric acid was obtained from BDH AnalaR. Antibodies were 
purchased from Abcam (USA).  
 
Copolymer synthesis The PMPC25-PDPA70 block copolymer was prepared by atom transfer radical 
polymerisation using a previously reported method.[1] Brielfly, MPC was polymerised first in 
methanol using [MPC]:[MEBr]:[CuBr]:[bpy] = 25:1:1:2. After 2 hours the reaction reached 98 % 
conversion at which point a solution of DPA (70 eq) in methanol was added via cannulla. After 40 h, 
1
H NMR studies indicated that both monomers had been consumed. After quenching with methanol 
purification was carried out by dialysis against pure water for 5 days. Subsequent lyophilisation 
yielded the white copolymer product. Characterisation by gel permeation chromatography indicated 
the block copolymer was well defined with an Mn value of 23,000 gmol
-1
 and Mw/Mn of 1.2.  
 
Polymersome preparation and antibody encapsulation. PMPC25-PDPA70 copolymer (20 mg) was 
added to a glass vial and dissolved in a solution of 2:1 chloroform: methanol, at a concentration of 3 
mg/ml.  The solvent was evaporated under vacuum in sterile conditions, resulting in a copolymer film 
deposited on the walls of the vial.  The copolymer film was rehydrated under sterile conditions using 
phosphate buffer saline (100 mM PBS) at pH 2 to form a 0.5 % w/w copolymer suspension. The 
solution was then sterilized by filtration (200 nm pore size). The solution pH was then increased to pH 
6 and antibodies solution (0.025 mg/ml) was added to the vesicle dispersion, which was then sonicated 
for 10 minutes. Polymersomes encapsulating antibodies were purified via gel permeation 
chromatography (GPC), using a size exclusion column containing Sepharose 4B and using PBS at pH 
7.3 to elute the vesicles. The fractions that contained polymersome encapsulating antibody, as 
determined by measuring the UV absorption at 546 nm using a Perkin Elmer Lambda 25 UV 
spectrophotometer, were used to treat the cells. Polymersomes encapsulating mouse monoclonal anti-
human--tubulin FITC labelled IgG antibody were added of trypan blue (0.100 ml) before sonication 
in order to enhance the final imaging resolution. This molecule quenched the fluorescently-labeled 
antibodies left over within the endosome. 
Cell culture. Primary human dermal fibroblasts (HDF) were isolated from skin obtained from 
abdominoplasty or breast reduction operations (according to local ethically approved guidelines, NHS 
Trust, Sheffield, UK). Primary cultures of fibroblasts were established as previously described
44
. 
Briefly, the epidermal layer of the skin was removed by trypsinisation and the remaining dermal layer 
was washed in PBS. The dermis was then minced using surgical blades and incubated in 0.5 % (w/v) 
collagenase A at 37˚C overnight in a humidified CO2 incubator. A cellular pellet was collected from 
the digest and cultured in DMEM (Sigma, UK) supplemented with 10 % (v/v) foetal calf serum, 2 mM 
L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.625 μg/ml amphotericin B. Cells 
were sub-cultured routinely using 0.02 % (w/v) EDTA and used for experimentation between passages 
4 and 8. 
Delivery of antibodies with PMPC25-PDPA70: Human Dermal Fibroblast (HDF) cells were seeded at a 
density of 1 x 10
5
 cells per well in a six-well plate (or on coverslips).Once cells achieved 80% 
confluence (typically within 48 h), the medium was replenished with an aqueous solution containing 
0.005 mM antibody-loaded polymersome (antibody concentration = 0.03 μM). Delivery of 
polymersomes encapsulating either AlexaFluor 546 goat Anti-human IgG or mouse monoclonal anti-
human--tubulin FITC-labelled IgG was achieved by incubation for 24 h at 37 °C. Polymersomes 
containing AlexaFluor 546-Rabbit polyclonal to human NFB-p65 antibody were loaded onto HDF 
cells for 6 h to ensure cellular uptake (this time period was selected based on previous experiments to 
establish optimal cellular uptake conditions). To activate NFB translocation, cells were exposed to 
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polymersomes containing anti-p65NFkB antibody for 6 h and then stimulated with bacterial 
lipopolysaccharide (LPS, Sigma-Aldrich) for 2 h. As an additional negative control to establish 
cellular background noise during microscopy studies, cells were treated with empty polymersomes in 
PBS (results not shown). Polymersomes containing mouse-anti human-Golgin-97monoclonal IgG 
were loaded for 24 h at 37 °C. Cells were then washed three times with PBS. Fresh media were added 
in addition to polymersomes containing AlexaFluor 546 goat Anti-mouse IgG. Cells were incubated 
with encapsulated secondary antibodies for 2 h. The cells were finally washed three times with PBS 
before being directly examined by CLSM using a Zeiss LSM 510M instrument.  
Stimulation emission depletion microscopy (STED) and sample preparation: Hela cells were treated 
overnight with polymersomes loaded with primary anti-Lamin a+c antibodies (Abcam, UK) labelled 
with the Atto 647N protein labelling kit (Sigma-Aldrich). Images were acquired using a Leica TCS 
SP5 Spectral Confocal with STED microscope (Leica Microsystems) with live cells after careful 
washing to remove any polymersomes that had not been internalised. Micrographs were acquired both 
in confocal mode and STED mode in order to confirm the higher resolution achieved in the latter case. 
 
Release of cytokines (IL-6, IL-8) from human dermal fibroblasts. 
Cytokine release was evaluated on the harvested culture supernatants of primary human dermal 
fibroblasts (3  10
5
 cells per well) seeded in 24-well multiwell plates (Falcon Labware, Oxnard, CA) 
and treated with polymersomes loaded with antip65NFB antibody and/or LPS. Cells were treated 
similarly to those described in the previous section. This time, after stimulation for 6 h using antibody-
loaded polymersomes at various concentrations  and/or 2 h LPS, media were changed to a serum-free 
medium (to avoid residual IL-8 and IL-6 being present in the serum) in order to collect 24 h-
conditioned medium. IL-6, and IL-8 were measured by immunoenzymatic methods using ELISA kits 
obtained from R & D System Inc, Minneapolis, USA. 
 
Immunofluorescence detection of NF-B activation in fibroblast by epifluorescence microscopy. 
Monolayers of cells were washed three times with PBS and fixed in 10 % (w/v) formalin (500 μl per 
well) for 1 h. Cells were then washed three times with PBS, permeabilised with 0.1 % (v/v) Triton 
X100 for 20 minutes, washed three times with PBS and unreactive binding sites were blocked with 5 
% (w/v) dried milk powder for 1 h.  Samples were again washed three times with PBS and incubated 
with a primary rabbit polyclonal anti-human IgG NF-B/p65 (c-20, Santa Cruz Biotechnology Inc., 
CA, USA) at a titre of 1:100 (v/v) in 1 % (w/v) milk powder in PBS at 4°C for 18 h.  Cells were 
washed three times with PBS and incubated with a biotinylated goat anti-rabbit secondary antibody at 
1:1000 (v/v) (Vector Laboratories, CA, USA) in 1 % (w/v) milk powder in PBS for 1 h at room 
temperature, Afterwards, wells were washed three times with PBS, and then incubated with 
streptavidin-FITC (Vector Laboratories, CA) at 1:100 (v/v) in PBS.  Finally, three further washes with 
PBS were conducted before cells were visualised by epifluorescence microscopy using an AXON 
ImageExpress system (Axon Instruments/Molecular Devices, Union City, CA, USA). Micrographs of 
immuno-labelled samples were recorded at ex = 495 nm / em = 515 nm for FITC/NF-B/p65 
visualisation and populations of cells per field of view were scored for relative activity  
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Supplementary information 
 
 
 
Figure S1: HDF cells were cultured in the presence of AlexaFluor 546 goat Anti-mouse IgG-loaded polymersomes. 
Intracellular delivery of antibodies was studied by confocal laser scanning microscopy (CLSM). (a) Live CLSM cell 
imaging of intracellular delivery of polymersomes encapsulating AlexaFluor 546 goat Anti-mouse IgG into live HDF cells; 
(b) a higher magnification image of (a) (x 3); (c) fixed CLSM cell imaging by traditional immunolabelling of HDF cells 
using AlexaFluor 546 goat Anti-mouse IgG; (d) a higher magnification image of  (c)  
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Figure S2:  TEM images showing sections of HDF cells obtained at different magnifications after incubation with 15 nm 
gold-labelled antibody-loaded polymerosmes, free antibodies, empty polymersomes and PBS. It is evident that the gold-
labelled antibodies are visible within the cell cytosol only when delivered using the polymersomes. Cell were imaged in 
two different area, the magnifation are also displaied using a color gradient to highlight the dense gold antibodies. 
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